Publication | Closed Access

Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse

Pancreatic CancerGastrointestinal OncologyMedicineGemcitabine Versus FolfirinoxGastroenterologyPathologyCancer TreatmentOncologyRadiation OncologyCancer ResearchAdvanced Pancreatic Adenocarcinoma